Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis’ Foradil Certihaler Approved For Asthma

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approval of asthma treatment follows receipt of two “approvable” letters.

You may also be interested in...



New Foradil Inhaler Falls Prey To Concerns About Single-Entity LABA Products

Novartis Foradil Certihaler (formoterol fumarate inhalation powder) is the first victim of a recommendation by several FDA advisory committees to withdraw the asthma indication for formoterol and salmeterol

New Foradil Inhaler Falls Prey To Concerns About Single-Entity LABA Products

Novartis Foradil Certihaler (formoterol fumarate inhalation powder) is the first victim of a recommendation by several FDA advisory committees to withdraw the asthma indication for formoterol and salmeterol

Sepracor COPD Treatment Approved

Brovana will be first-to-market long-acting bronchodilator developed in an inhalation solution for use with a nebulizer.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS063562

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel